Week in Washington 032422

Week in Washington is brought to you by Michael Cohen, PhD. Tune in each week to read the latest on healthcare policy and get a glimpse of what’s on the horizon

Week in Washington



There is increasing chatter in DC around a bipartisan bill to cap insulin costs. In particular, Senate Majority leader Chuck Schumer announced a vote that would be scheduled in late April to cap insulin costs and more generally control insulin prices. Such a bill could have dramatic effects, given the utilization of insulin drugs. The announcement also highlights there is movement at the moment for an extension of the American Rescue plan ACA subsidies (i.e., unlikely anything would be passed before May).


Child Vaccine Coming?

There were a number of items on the COVID vaccine front. Moderna announced that its clinical trial for a Covid Vaccine for 6 months to 6 years showed positive data. As a result, Moderna will submit a request for authorization for approval of its vaccine to the FDA in the coming weeks.

Fourth Dose

There’s increasingly a push by the Biden Administration for a fourth dose of the Covid vaccine to be approved soon. The problem is that a lack of Covid funding means that there may not be sufficient supply to meet the needs of the general public for a fourth dose.

ACA Anniversary

The Affordable Care Act celebrated its 12th anniversary (yep the ACA is a tween) this week. HHS released a series of report on the impact of the ACA on health coverage, the individual market, and Medicaid.


CMS also made a number of announcements in regards to the individual market including:



Previous editions: 

03/17/2022: Week in Washington

03/10/2022: Week in Washington

03/03/2022: Week in Washington

02/24/2022: Week in Washington


02/17/2022: Week in Washington

02/10/2022: Week in Washington

02/03/2022: Week in Washington

01/27/2022: Week in Washington

Read More Wakely Insights
©2017-2022 Wakely Consulting Group LLC  All Rights Reserved. The materials in this document represent the opinion of the authors and are not representative of the views of Wakely Consulting Group. Wakely does not certify the information, nor does it guarantee the accuracy and completeness of such information. Use of this information is voluntary.